The evaluation efficacy of Desmopressin in improvement coagulation status of patients with combined factor V and VIII deficiency.

Phase 2

Completed

• Conditions: Combined factor V and VIII deficiency.; Hereditary deficiency of other clotting factors

• Registration Number: IRCT2015020120894N1
• Lead Sponsor: Vice chancellor for research, Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Confirmed affection with combined factor V and VIII deficiency using an identification card of hemophilia center or coagulation laboratory sheet showing diagnosis of combined factor V and VIII deficiency;
Having more than 18 years old officially;
Agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume;
Not infusion of factor VIII during last 48 hours;
Not infusion of fresh frozen plasma or cryopercipitate during last 48 hours;
6-Not having active bleeding in time of accompanying in research.
Exclusion criteria:
1-Affection to other similar coagulation disorders, inter alia, combined factor VIII & IX deficiency.
2-Havingless than 18 years old officially.
3-Not agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume.
4-Infusion of factor VIII during last 48 hours.
5-Infusion of fresh frozen plasma during last 48 hours.
6-Having active bleeding in time of accompanying in research.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma level of coagulation factor V. Timepoint: One hour after termination of DDAVP injection. Method of measurement: According to standard one-stage APTT method.;Plasma level of coagulation factor VIII. Timepoint: One hour after termination of DDAVP injection. Method of measurement: According to standard one-stage APTT method.

Secondary Outcome Measures

Name	Time	Method
?Flushing. Timepoint: One hour after injection of Desmopressin. Method of measurement: Appearance of flushing in face and felling of warmness by the patients.